Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras

Journal of Clinical Virology

Volumn 49, Issue 4, 2010, Pages 239-244

  Murillo, Wendy ^a,b,c   Paz Bailey, Gabriela ^d,e   Morales, Sonia ^e   Monterroso, Edgar ^f   Paredes, Mayte ^g   Dobbs, Trudy ^f   Parekh, Bharat S ^f   Albert, Jan ^b,c   Rivera, Ivette Lorenzana de ^a  

^a NATIONAL AUTONOMOUS UNIVERSITY OF HONDURAS   (Honduras)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Tephinet Inc   (United States)

^e Valle University of Guatemala   (Guatemala)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g HIV/AIDS National Program   (Honduras)

Author keywords

Drug resistance; HIV 1; Honduras; Newly diagnosed; Recent infections

Indexed keywords

EFAVIRENZ; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; ASSAY; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; HONDURAS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MUTATION; POPULATION; PREVALENCE; PRIORITY JOURNAL; SEX ROLE; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HONDURAS; HUMANS; MALE; MIDDLE AGED; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 78149499458     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.03.013     Document Type: Article

References (41)

1. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338(March (13)):853-860.
2. Murphy E.L., Collier A.C., Kalish L.A., Assmann S.F., Para M.F., Flanigan T.P., et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001, 135(July (1)):17-26.
3. Mocroft A., Ledergerber B., Katlama C., Kirk O., Reiss P., d'Arminio Monforte A., et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362(July (9377)):22-29.
4. Hammer S.M., Saag M.S., Schechter M., Montaner J.S., Schooley R.T., Jacobsen D.M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Top HIV Med 2006, 14(August-September (3)):827-843.
5. UNAIDS UNICEF, WHO. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress report; June 2008.
6. Reporte Nacional de VIH/SIDA. Tegucigalpa, Honduras: Programa Nacional de ITS/VIH/SIDA; January 2007.
7. Erice A., Mayers D.L., Strike D.G., Sannerud K.J., McCutchan F.E., Henry K., et al. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993, 328(April (16)):1163-1165.
8. Boden D., Hurley A., Zhang L., Cao Y., Guo Y., Jones E., et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282(September (12)):1135-1141.
9. Kijak G.H., Pampuro S.E., Avila M.M., Zala C., Cahn P., Wainberg M.A., et al. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antivir Ther 2001, 6(March (1)):71-77.
10. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347(August (6)):385-394.
11. Baggaley R.F., Garnett G.P., Ferguson N.M. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006, 3(April (4)):e124.
12. Shet A., Berry L., Mohri H., Mehandru S., Chung C., Kim A., et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr Apr 1 2006, 41(4):439-446.
13. Chaix M.L., Descamps D., Wirden M., Bocket L., Delaugerre C., Tamalet C., et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009, 23(March (6)):717-724.
14. The-SPREAD-Programme Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008, 22(March (5)):625-635.
15. Weinstock H.S., Zaidi I., Heneine W., Bennett D., Garcia-Lerma J.G., Douglas J.M., et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004, 189(June (12)):2174-2180.
16. Booth C.L., Garcia-Diaz A.M., Youle M.S., Johnson M.A., Phillips A., Geretti A.M. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007, 59(March (3)):517-524.
17. Rodrigues R., Scherer L.C., Oliveira C.M., Franco H.M., Sperhacke R.D., Ferreira J.L. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res 2006, 116(March (1-2)):201-207.
18. Lama J.R., Sanchez J., Suarez L., Caballero P., Laguna A., Sanchez J.L., et al. Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 2006, 42(August (4)):501-505.
19. Dilernia D.A., Lourtau L., Gomez A.M., Ebenrstejin J., Toibaro J.J., Bautista C.T., et al. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina. AIDS 2007, 21(June (10)):1355-1360.
20. Petroni A., Deluchi G., Pryluka D., Rotryng F., Bortolozzi R., Lopardo G., et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 2006, 42(August (4)):506-510.
21. Gonsalez C.R., Alcalde R., Nishiya A., Barreto C.C., Silva F.E., de Almeida A., et al. Drug resistance among chronic HIV-1-infected patients naive for use of anti-retroviral therapy in Sao Paulo city. Virus Res 2007, 129(November (2)):87-90.
22. Ferreira J.L., Thomaz M., Rodrigues R., Harrad D., Oliveira C.M., Oliveira C.A., et al. Molecular characterisation of newly identified HIV-1 infections in Curitiba, Brazil: preponderance of clade C among males with recent infections. Mem Inst Oswaldo Cruz 2008, 103(December (8)):800-808.
23. Viani R.M., Hsia K., Hubbard P., Ruiz-Calderon J., Lozada R., Alvelais J., et al. Prevalence of primary HIV-1 drug resistance in pregnant women and in newly diagnosed adults at Tijuana General Hospital, Baja California, Mexico. Int J STD AIDS 2007, 18(April (4)):235-238.
24. Escoto-Delgadillo M., Vazquez-Valls E., Ramirez-Rodriguez M., Corona-Nakamura A., Amaya-Tapia G., Quintero-Perez N., et al. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med 2005, 6(November (6)):403-409.
25. Lloyd B., O'Connell R.J., Michael N.L., Aviles R., Palou E., Hernandez R., et al. Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning of the National Antiretroviral Therapy Program. AIDS Res Hum Retroviruses 2008, 24(April (4)):529-535.
26. Bennett D.E., Myatt M., Bertagnolio S., Sutherland D., Gilks C.F. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008, 13(Suppl. 2):25-36.
27. Bennett D.E., Bertagnolio S., Sutherland D., Gilks C.F. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008, 13(Suppl. 2):1-13.
28. Myatt M., Bennett D.E. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 2008, 13(Suppl. 2):37-48.
29. Shepherd B.E., Rossini A.J., Soto R.J., De Rivera I.L., Mullins J.I. Sampling designs for HIV molecular epidemiology with application to Honduras. AIDS Res Hum Retroviruses 2005, 21(November (11)):907-914.
30. Paz-Bailey G., Morales-Miranda S., Jacobson J.O., Gupta S.K., Sabin K., Mendoza S., et al. High rates of STD and sexual risk behaviors among Garifunas in Honduras. J Acquir Immune Defic Syndr 2009, 51(May (Suppl. 1)):S26-S34.
31. Johnston LG, Paz-Bailey G, Morales Miranda S, Morgan M, Alvarez B, Hickman L, et al. High prevalence of Mycoplasm genitalium among female sex workers in Honduras: implications for the spread of HIV and other sexually transmitted Infections. J Acquir Immune Defic Syndr; in press.
32. Parekh B.S., Kennedy M.S., Dobbs T., Pau C.P., Byers R., Green T., et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 2002, 18(March (4)):295-307.
33. Dobbs T., Kennedy S., Pau C.P., McDougal J.S., Parekh B.S. Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 2004, 42(June (6)):2623-2628.
34. Lindstrom A., Albert J. A simple and sensitive 'in-house' method for determining genotypic drug resistance in HIV-1. J Virol Methods 2003, 107(January (1)):45-51.
35. Murillo W., de Rivera I.L., Parham L., Jovel E., Palou E., Karlsson A.C., et al. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med 2010, 11(2):95-103.
36. Bennett D.E., Camacho R.J., Otelea D., Kuritzkes D.R., Fleury H., Kiuchi M., et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009, 4(3):e4724.
37. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24(August (8)):1596-1599.
38. Jayaraman G.C., Archibald C.P., Kim J., Rekart M.L., Singh A.E., Harmen S., et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006, 42(May (1)):86-90.
39. Vercauteren J., Wensing A.M., van de Vijver D.A., Albert J., Balotta C., Hamouda O., et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009, 200(November (10)):1503-1508.
40. Casado J.L., Hertogs K., Ruiz L., Dronda F., Van Cauwenberge A., Arno A., et al. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS 2000, 14(January (2)):F1-F7.
41. Liu T.F., Shafer R.W. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006, 42(June (11)):1608-1618.